Ancora Advisors LLC Purchases New Stake in Omeros Corporation $OMER

Key Points

• Ancora Advisors acquired 168,750 Omeros shares worth approximately $1.6 million, while institutional investors collectively own 48.79% of the company.
• Omeros shares rose 5.7% to $19.25, near their 12-month high of $19.65. The company exceeded quarterly expectations with EPS of $0.02 versus the anticipated loss of $0.27 and revenue of $28.53 million.
• Analyst sentiment remains a Moderate Buy, with an average price target of $38, although insiders sold 30,906 shares worth about $568,305 over the past three months.

Ancora Advisors LLC purchased a new stake in shares of Omeros Corporation (NASDAQ:OMER - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 168,750 shares of the biopharmaceutical company's stock, valued at approximately $1,605,000. Ancora Advisors LLC owned approximately 0.23% of Omeros as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. UBS Group AG boosted its position in Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company's stock worth $38,180,000 after purchasing an additional 1,513,893 shares during the period. Dimensional Fund Advisors LP raised its position in Omeros by 85.2% in the first quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company's stock valued at $1,897,000 after purchasing an additional 82,646 shares during the period. Corient Private Wealth LLC raised its position in Omeros by 13.0% in the fourth quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company's stock valued at $11,817,000 after purchasing an additional 79,263 shares during the period. Compass Financial Management LLC acquired a new position in shares of Omeros during the second quarter worth about $312,000. Finally, Quantinno Capital Management LP lifted its stake in shares of Omeros by 145.4% during the first quarter. Quantinno Capital Management LP now owns 61,541 shares of the biopharmaceutical company's stock worth $650,000 after purchasing an additional 36,467 shares in the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Weiss Ratings upgraded Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, August 5th. Zacks Research cut Omeros from a "strong-buy" rating to a "hold" rating in a report on Monday, July 13th. HC Wainwright reaffirmed a "buy" rating on shares of Omeros in a research report on Monday, July 27th. Finally, Wall Street Zen upgraded shares of Omeros from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $38.00.

Omeros Trading Up 5.7%

Shares of NASDAQ:OMER opened at $19.25 on Friday. The firm has a market cap of $1.39 billion, a PE ratio of 15.04 and a beta of 2.54. The company has a fifty day simple moving average of $12.48 and a 200 day simple moving average of $11.98. Omeros Corporation has a 12-month low of $3.94 and a 12-month high of $19.65.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. As a group, equities research analysts forecast that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Insider Activity

In other Omeros news, Director Thomas J. Cable sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $18.45, for a total transaction of $276,750.00. Following the sale, the director owned 35,067 shares in the company, valued at $646,986.15. This represents a 29.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO David J. Borges sold 10,000 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the transaction, the chief accounting officer directly owned 5,906 shares in the company, valued at approximately $111,918.70. This represents a 62.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 30,906 shares of company stock valued at $568,305. 10.50% of the stock is owned by corporate insiders.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.